World-First Cancer Vaccine Could Cut the Chances of Skin Cancer Coming Back

Scientists have announced a major breakthrough in the fight against skin cancer. A new personalised vaccine, used alongside an existing cancer drug, cut the risk of patients dying or their cancer coming back by 42 per cent. The results come from a large clinical trial that followed more than 1,100 patients around the world. Doctors are calling it the start of a whole new era in cancer treatment.

The vaccine targets melanoma, which is the most dangerous type of skin cancer. In the UK alone, melanoma kills around 2,600 people every year. Normally, only about one in three patients with the most serious form of the disease survive for five years after their diagnosis. That makes new treatments like this one especially important.

The vaccine is called Intismeran, and it works in a very personal way. Doctors take cells from each patient's own tumour and use them to teach the patient's immune system to find and attack cancer cells. Because every patient's cancer is slightly different, each vaccine is made specifically for that one person. This is what scientists mean when they call it a 'personalised' vaccine.

The trial tested the vaccine together with an immunotherapy drug called Keytruda. Immunotherapy is a type of treatment that helps the body's own immune system fight cancer. In the study, 1,137 adults took part. About two-thirds received both the vaccine and Keytruda, while the rest received Keytruda and a placebo, which is a harmless dummy treatment with no medicine in it.

The results were impressive. After two years, 82.2 per cent of patients who received both the vaccine and Keytruda were still cancer-free. In comparison, 70 per cent of those who only received Keytruda stayed cancer-free. The vaccine also reduced the chance of melanoma spreading to other parts of the body by 38 per cent. Those are big differences that could save many lives.

One patient who took part in the trial is Tony Chapman, a 75-year-old retired businessman from North Northamptonshire in England. He was diagnosed with stage three melanoma in 2019 and had a tumour removed from his chest. Four years later, doctors found a lump under his armpit and he needed more surgery. He joined the international trial at Addenbrooke's Hospital in Cambridge and, after finishing treatment, he remains cancer-free today.

Mr Chapman does not know whether he received the real vaccine or the placebo. But he says he is glad he took part. 'I couldn't get over how groundbreaking it sounded,' he said. 'The opportunity to play a small part in furthering scientific research and potentially helping others along the way, was too exciting to miss out on.' His positive attitude reflects the hope that many patients and doctors feel about this new approach.

The vaccine was developed by drug companies MSD and Moderna — the same company that made one of the COVID-19 vaccines. They are now testing whether similar personalised vaccines can work against other types of cancer, including kidney, bladder, and lung cancer. Professor Pippa Corrie, a cancer specialist at Addenbrooke's Hospital who helped run the trial, said the vaccine 'is a whole new approach to cancer treatment.' She explained that it is designed to work better than standard drugs because it takes each person's differences into account.

Not all experts think the vaccine is ready to replace current treatments just yet. Scientists who were not part of the study say more research is needed to find out exactly which patients will benefit most. Professor Alan Melcher, from The Institute of Cancer Research in London, said vaccines are unlikely to replace existing treatments across the board. Instead, he believes they will become 'another powerful tool' that doctors can combine with other therapies like immunotherapy.

Dr Lennard Lee, a cancer vaccine researcher at the University of Oxford, said this trial shows something very exciting about the future of medicine. He pointed out that every patient's cancer is different, and every person's immune system is different too. Rather than giving all patients the same medicine, this new approach designs a vaccine around the unique 'genetic fingerprint' of each person's tumour. 'This is a major breakthrough for cancer vaccine research,' he said.